MedTrace Logo

Casodex/Zoladex Biomarkers in Localised Prostate Cancer

NCT00293696 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2007-05-08

No results posted yet for this study

Summary

To evaluate anti-androgen (bicalutamide) induced biological and molecular changes in prostate comparison to chemical castration induced (goserelin) ones

Conditions

Interventions

DRUG

bicalutamide (Casodex), goserelin (Zoladex)

Sponsors & Collaborators

  • Tampere University

    lead OTHER

Principal Investigators

  • Teuvo L Tammela, Professor · Tampere University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Completion
2006-11-30

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00293696 on ClinicalTrials.gov